Bio-Techne (TECH) 10-Q 9 May 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2022	May 03, 2022
Cover
Entity Central Index Key	0000842023
Entity Registrant Name	BIO-TECHNE Corp
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	0-17272
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1427402
Entity Address, Address Line One	614 McKinley Place N.E.
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55413
City Area Code	612
Local Phone Number	379-8854
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	TECH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,233,511

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net sales	$ 290,376	$ 243,552	$ 817,371	$ 672,004
Cost of sales	88,918	75,278	261,225	215,098
Gross margin	201,458	168,274	556,146	456,906
Operating expenses:
Selling, general and administrative	89,269	82,596	276,137	238,310
Research and development	21,742	17,052	63,992	49,882
Total operating expenses	111,011	99,648	340,129	288,192
Operating income	90,447	68,626	216,017	168,714
Other income (expense)	(21,675)	(23,272)	6,317	(27,652)
Earnings before income taxes	68,772	45,354	222,334	141,062
Income taxes (benefit)	8,628	(48)	21,150	16,121
Net earnings, including noncontrolling interest	60,144	45,402	201,184	124,941
Net earnings (loss) attributable to noncontrolling interest	(595)	(380)	(9,343)	(509)
Net earnings attributable to Bio-Techne	60,739	45,782	210,527	125,450
Other comprehensive income (loss):
Foreign currency translation adjustments	(2,851)	(1,142)	(9,573)	27,700
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	7,179	1,288	11,745	5,490
Other comprehensive income (loss)	4,328	146	2,172	33,190
Other comprehensive income (loss) attributable to noncontrolling interest	(1)	(69)	26	14
Other comprehensive income (loss) attributable to Bio-Techne	4,329	215	2,146	33,176
Comprehensive income attributable to Bio-Techne	$ 65,068	$ 45,997	$ 212,673	$ 158,626
Earnings per share attributable to Bio-Techne:
Basic (in dollars per share)	$ 1.55	$ 1.18	$ 5.36	$ 3.24
Diluted (in dollars per share)	$ 1.48	$ 1.12	$ 5.12	$ 3.11
Weighted average common shares outstanding:
Basic (in shares)	39,272	38,856	39,225	38,693
Diluted (in shares)	40,969	40,676	41,073	40,305

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 160,821	$ 199,091
Short-term available-for-sale investments	70,351	32,463
Accounts receivable, less allowance for doubtful accounts of $1,522 and $1,229, respectively	202,095	145,385
Inventories	128,283	116,748
Other current assets	31,558	16,919
Total current assets	593,108	510,606
Property and equipment, net	218,398	207,907
Right of use asset	63,450	73,834
Goodwill	827,618	843,067
Intangible assets, net	551,342	615,968
Other assets	45,976	11,575
Total assets	2,299,892	2,262,957
Current liabilities:
Trade accounts payable	30,859	29,384
Salaries, wages and related accruals	55,642	51,294
Accrued expenses	19,998	15,282
Contract liabilities	23,107	18,995
Income taxes payable	9,788	5,336
Operating lease liabilities - current	11,864	11,602
Contingent consideration payable		4,000
Current portion of long-term debt obligations	12,500	12,500
Other current liabilities	3,080	3,891
Total current liabilities	166,838	152,284
Deferred income taxes	99,301	93,125
Long-term debt obligations	246,514	328,827
Long-term contingent consideration payable	4,800	25,400
Operating lease liabilities	56,348	67,625
Other long-term liabilities	12,769	24,462
Bio-Techne's Shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,263,444 and 38,955,484, respectively	393	390
Additional paid-in capital	636,321	534,411
Retained earnings	1,132,807	1,085,461
Accumulated other comprehensive loss	(55,145)	(57,291)
Total Bio-Techne's shareholders' equity	1,714,376	1,562,971
Noncontrolling interest	(1,054)	8,263
Total shareholders' equity	1,713,322	1,571,234
Total liabilities and shareholders' equity	$ 2,299,892	$ 2,262,957

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 1,522	$ 1,229
Undesignated capital stock, no par (in dollars per share)	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	39,263,444	38,955,484
Common stock, shares outstanding (in shares)	39,263,444	38,955,484

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings, including noncontrolling interest	$ 201,184	$ 124,941
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	75,203	63,075
Costs recognized on sale of acquired inventory	1,596	91
Deferred income taxes	7,888	(6,023)
Stock-based compensation expense	33,777	39,174
Contingent consideration payments - operating	(3,300)	(155)
Fair value adjustment to contingent consideration payable	(20,600)	6,188
Fair value adjustment on available for sale investments	(15,569)	10,234
Asset impairment restructuring	546	0
Eminence impairment	18,715	0
Leases, net	(974)	83
Other operating activity	549	(608)
Change in operating assets and operating liabilities, net of acquisition:
Trade accounts and other receivables, net	(60,930)	(32,710)
Inventories	(16,034)	(4,115)
Prepaid expenses	(3,576)	414
Trade accounts payable, accrued expenses, contract liabilities, and other	11,229	12,198
Salaries, wages and related accruals	2,059	13,829
Income taxes payable	(9,208)	3,528
Net cash provided by (used in) operating activities	222,555	230,144
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturities of available-for-sale investments	26,055	66,377
Purchases of available-for-sale investments	(47,998)	(39,684)
Additions to property and equipment	(31,338)	(32,985)
Acquisitions, net of cash acquired		(9,765)
Investment in unconsolidated entity		(556)
Investment of forward purchase contract	(25,000)
Net cash provided by (used in) investing activities	(78,281)	(16,613)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends	(37,646)	(37,174)
Proceeds from stock option exercises	68,346	54,992
Re-purchases of common stock	(102,132)	(43,178)
Borrowings under line-of-credit agreement	90,000	0
Repayments of long-term debt	(172,375)	(141,375)
Contingent consideration payments - financing	(700)	0
Other financing activity	(22,618)	(13,504)
Net cash provided by (used in) financing activities	(177,125)	(180,239)
Effect of exchange rate changes on cash and cash equivalents	(5,419)	6,219
Net change in cash and cash equivalents	(38,270)	39,511
Cash and cash equivalents at beginning of period	199,091	146,625
Cash and cash equivalents at end of period	160,821	186,136
Supplemental disclosure of cash flow information:
Cash paid for income taxes	22,965	17,957
Cash paid for interest	$ 8,522	$ 10,729

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Basis of Presentation and Summary of Significant Accounting Policies: The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2021, included in the Company's Annual Report on Form 10-K for fiscal 2021. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2021. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. During the nine months ended March 31, 2022, the Company operated under two operating segments, Protein Sciences and Diagnostics and Genomics. The operating segments the Company operated under were consistent with the Company's operating segments disclosed in the Company's Annual Report on Form 10-K for fiscal 2021. Goodwill: Given the upcoming liquidation process to dispose of the Eminence assets, the Company identified a triggering event and performed impairment testing during the second quarter of fiscal 2022. The impairment testing resulted in a full impairment of the Eminence goodwill and intangible assets, which resulted in charges of $8.3 million and $8.6 million, respectively, for the nine-months ended March 31, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. The Company recorded the impairment charges within the General and Administrative line in the Consolidated Income Statement. The impairment charges recorded within Net Earnings Attributable to Bio-Techne were reduced by approximately $8 million recorded within Net Earnings Attributable to Noncontrolling Interests. The remaining net tangible assets of Eminence included in our Consolidated Balance Sheet as of March 31, 2022, were approximately $4 million and primarily consisted of fixed assets and related deposits of $3.8 million, inventory of $0.8 million, receivables of $0.7 million, and other current assets of $0.2 million. The Company also had $2.2 million related to current liabilities. The Company holds a financial interest of approximately 57.4% in those tangible assets in the upcoming liquidation process. Investments The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in annual earnings before interest, taxes, depreciation, and amortization (EBITDA) at any point prior to December 31, 2027. Once triggered, the Company is required to make a payment of $231 million in exchange for a 19.9% ownership stake. If Wilson Wolf doesn’t achieve the revenue and EBITDA targets by December 31, 2027, the agreement will expire. Once the first part of the forward contract is triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. The approximate multiple for total expected payments of the second forward contract is 4.4 times the annual revenue of Wilson Wolf. The Company has elected to apply the measurement alternative as detailed under ASC 321-10-35-2 for the Wilson Wolf investment. The Company recorded the $25 million payment as a cost basis investment within Other long-term assets on the Consolidated Balance Sheet. Restructuring actions In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were substantially complete as of the end of the third fiscal quarter, with final remaining payouts expected to occur in the fourth quarter of fiscal 2022. As a result of the restructuring activities, an estimated pre-tax charge of $1.2 million was recorded within our Diagnostics and Genomics segment during the first quarter of fiscal 2022. Additional charges of approximately $0.5 million and $(0.3) million were recorded in the second and third quarters of fiscal 2022, respectively. These additional charges related to the refinement of our estimated close down costs as well as miscellaneous shut-down costs incurred during the quarter. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the nine months ended March 31, 2022 were recorded within operating income on the income statement as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Employee ​ Asset ​ ​ ​ Severance Impairment and other Total Selling, general and administrative ​ $ 649 ​ $ 750 ​ $ 1,399 ​ Restructuring actions, including cash and non-cash impacts, are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Employee ​ Asset ​ ​ ​ Severance Impairment and other Total Accrued restructuring action balances as of September 30, 2021 (1) ​ $ 639 ​ $ 364 ​ $ 1,003 Incremental expense incurred in the second quarter of fiscal 2022 ​ ​ — ​ ​ 242 ​ ​ 242 Cash payments ​ ​ (370) ​ ​ (242) ​ ​ (612) Adjustments ​ ​ 301 ​ ​ (37) ​ ​ 264 Accrued restructuring actions balances as of December 31, 2021 ​ ​ 570 ​ ​ 327 ​ ​ 897 Cash payments ​ ​ (200) ​ ​ (272) ​ ​ (472) Adjustments (2) ​ ​ (345) ​ ​ (28) ​ ​ (373) Accrued restructuring actions balances as of March 31, 2022 ​ $ 25 ​ $ 27 ​ $ 52 ​ (1) The expense recorded for the three months ended September 30, 2021 of $1.2 million included $0.2 million related to the non-cash impairment of fixed assets. (2) During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This charge is recorded within Other current liabilities as of March 31, 2022. There were no cash payments or adjustments related to this restructuring during the quarter ended March 31, 2022. Recently Adopted Accounting Pronouncements There were no accounting pronouncements adopted in the nine months ended March 31, 2022. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2021.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 2. Revenue Recognition: Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time. Prior to fiscal 2021, the Company has not recognized revenue upon completion of the performance obligation for laboratory services, but rather upon cash receipt, which was subsequent to the performance obligation being satisfied. The Company accounted for these services based on cash receipts as we did not have significant historical experience collecting payments from Medicare or other insurance providers and considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Given Medicare coverage for our laboratory services became effective on December 1, 2019, the Company considered it to have sufficient data to estimate variable consideration as of July 1, 2020 for laboratory services that are reimbursed by Medicare. The amount of cash received in fiscal 2021 for laboratory services reimbursed by Medicare that were performed prior to July 1, 2020 was approximately $0.5 million. The Company continues to record revenue based on cash receipts for laboratory services not reimbursed by Medicare, as the variable consideration remains constrained. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company’s unfulfilled performance obligations were not material as of March 31, 2022. Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception. Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both. Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of March 31, 2022 are not material. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of March 31, 2022 and June 30, 2021 were approximately $25.1 million and $20.0 million, respectively. Contract liabilities as of June 30, 2021 subsequently recognized as revenue during the quarter and nine month period ended March 31, 2022 were approximately $1.9 million and $15.2 million, respectively. Contract liabilities in excess of one year are included in Other long-term liabilities on the consolidated balance sheet. Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Consumables ​ $ 239,171 ​ $ 198,818 ​ $ 657,568 ​ $ 542,909 Instruments ​ 28,899 ​ 24,748 ​ 92,121 ​ 70,849 Services ​ 17,815 ​ 14,503 ​ 51,426 ​ 45,142 Total product and services revenue, net ​ $ 285,885 ​ $ 238,069 ​ $ 801,115 ​ $ 658,900 Royalty revenues ​ 4,491 ​ 5,483 ​ 16,256 ​ 13,104 Total revenues, net ​ $ 290,376 ​ $ 243,552 ​ $ 817,371 ​ $ 672,004 ​ Revenue by geography is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 United States ​ $ 163,976 ​ $ 131,586 ​ $ 447,045 ​ $ 359,586 EMEA, excluding United Kingdom ​ 55,301 ​ 54,552 ​ 164,003 ​ 147,622 United Kingdom ​ 12,920 ​ 11,213 ​ 37,240 ​ 29,599 APAC, excluding Greater China ​ 21,100 ​ 19,002 ​ 58,204 ​ 52,744 Greater China ​ 26,554 ​ 20,467 ​ 85,997 ​ 63,685 Rest of World ​ 10,525 ​ 6,732 ​ 24,882 ​ 18,768 Net Sales ​ $ 290,376 ​ $ 243,552 ​ $ 817,371 ​ $ 672,004 ​

Selected Balance Sheet Data

Selected Balance Sheet Data	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 3. Selected Balance Sheet Data: Inventories: Inventories consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ 2022 2021 Raw materials ​ $ 69,263 ​ $ 55,096 Finished goods (1) ​ 64,742 ​ 67,108 Inventories, net ​ $ 134,005 ​ $ 122,204 ​ (1) Finished goods inventory of $5,722 and $5,456 included within other long-term assets in the respective March 31, 2022 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. ​ Property and Equipment: Property and equipment consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ 2022 2021 Land ​ $ 8,603 ​ $ 8,612 Buildings and improvements ​ 225,378 ​ 190,661 Machinery and equipment ​ ​ 164,665 ​ ​ 149,410 Construction in progress ​ 26,508 ​ 49,073 Property and equipment, cost ​ 425,154 ​ 397,756 Accumulated depreciation and amortization ​ (206,756) ​ (189,849) Property and equipment, net ​ $ 218,398 ​ $ 207,907 ​ Intangible Assets: Intangible assets consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ Developed technology ​ $ 543,977 ​ $ 552,160 Trade names ​ 147,311 ​ 147,640 Customer relationships ​ 228,943 ​ 232,493 Patents ​ 3,249 ​ 2,926 Other intangibles ​ 6,313 ​ 6,316 Definite-lived intangible assets ​ 929,793 ​ 941,535 Accumulated amortization ​ (401,151) ​ (348,267) Definite-lived intangibles assets, net ​ 528,642 ​ 593,268 In process research and development ​ 22,700 ​ 22,700 Total intangible assets, net ​ $ 551,342 ​ $ 615,968 ​ Changes to the carrying amount of net intangible assets for the period ended March 31, 2022 consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Beginning balance ​ $ 615,968 Acquisitions ​ — Other additions ​ 283 Amortization expense ​ (55,731) Currency translation ​ (615) Eminence impairment (1) ​ ​ (8,563) Ending balance ​ $ 551,342 ​ The estimated future amortization expense for intangible assets as of March 31, 2022 is as follows (in thousands): ​ ​ ​ ​ ​ 2022 remainder $ 18,478 2023 ​ 71,725 2024 ​ 68,857 2025 ​ 65,621 2026 ​ 61,876 Thereafter ​ 242,085 Total ​ $ 528,642 ​ (1) As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22. Goodwill: Changes to the carrying amount of goodwill for the period ended March 31, 2022 consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics and ​ ​ ​ Protein Sciences ​ Genomics ​ Total Beginning balance ​ $ 392,717 ​ $ 450,350 ​ $ 843,067 Acquisitions (1) ​ — ​ (4,407) ​ (4,407) Eminence impairment ​ ​ (8,275) ​ ​ — ​ ​ (8,275) Currency translation ​ (2,588) ​ (179) ​ (2,767) Ending balance ​ $ 381,854 ​ $ 445,764 ​ $ 827,618 ​ (1) We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2021. No indicators of impairment were identified as part of our assessment. During the quarter ended September 30, 2021, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment. As disclosed in Note 1, the Company identified a triggering event and a goodwill impairment charge of $8.3 million in the second quarter of fiscal 2022. No additional triggering events or items beyond the upcoming Eminence liquidation were identified during the quarter ended March 31, 2022. The impairment of the Eminence goodwill is the only impairment of goodwill recorded since the adoption of Financial Accounting Standards Board ("FASB") ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

Acquisitions

Acquisitions	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4. Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred. Fiscal year 2021 Acquisitions Asuragen, Inc. On April 6, 2021, the Company acquired all of the ownership interests of Asuragen, Inc. (Asuragen) for approximately $216 million, net of cash acquired, plus contingent consideration of up to $105.0 million, subject to certain revenue thresholds. The Asuragen acquisition adds a leading portfolio of best in-class molecular diagnostic and research products, including genetic screening, oncology testing kits, molecular controls, a GMP compliant manufacturing facility, and a CLIA-certified laboratory. The transaction was accounted for in accordance with ASC 805, Business Combinations Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the quarter ended March 31, 2022 were approximately $8.6 million and $0.1 million, respectively. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the nine months ended March 31, 2022 were approximately $25.0 million and $3.7 million, respectively. ​ The allocation of purchase consideration related to Asuragen was completed in the third quarter of fiscal year 2022. The fair values of the assets acquired and liabilities assumed at acquisition date and the updated final amounts as of March 31, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preliminary allocation at ​ Adjustments Final allocation at ​ acquisition date ​ to fair value ​ March 31, 2022 Current assets, net of cash $ 10,422 ​ $ ​ ​ $ 10,422 Equipment and other long-term assets 3,762 ​ ​ ​ ​ 3,762 Intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ Developed technology 107,000 ​ ​ ​ ​ 107,000 In-process research and development 22,700 ​ ​ ​ ​ 22,700 Customer relationships 11,700 ​ ​ ​ ​ 11,700 Trade names 2,000 ​ ​ ​ ​ 2,000 Non-competition agreement 1,000 ​ ​ ​ ​ 1,000 Goodwill 94,970 ​ ​ (4,407) ​ 90,563 Total assets acquired 253,554 ​ ​ (4,407) ​ 249,147 ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities 4,003 ​ ​ 960 ​ 4,963 Deferred income taxes, net 15,664 ​ ​ (5,367) ​ 10,297 Net assets acquired $ 233,887 ​ $ — ​ $ 233,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash paid, net of cash acquired 215,587 ​ ​ ​ ​ 215,587 Contingent consideration payable 18,300 ​ ​ ​ ​ 18,300 Net assets acquired $ 233,887 ​ $ — ​ $ 233,887 ​ As summarized in the table, there were adjustments totaling $4.4 million to goodwill during the measurement period. These adjustments relate to refinements within our deferred tax amounts based on factors existing on the acquisition date. ​ Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology, in-process research and development, and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 16 years. The amount recorded for trade names and the non-competition agreement is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names and the non-competition agreement is estimated to be 5 years and 3 years, respectively. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Note 5 . Fair Value Measurements: The Company’s financial instruments include cash and cash equivalents, available for sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation. The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ value as of ​ Fair Value Measurements Using ​ ​ March 31, ​ Inputs Considered as ​ ​ 2022 ​ Level 1 ​ Level 2 ​ Level 3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Exchange traded securities (1) ​ $ 55,851 ​ $ 55,851 ​ $ — ​ $ — Certificates of deposit (2) ​ 14,500 ​ 14,500 ​ — ​ — Derivative instruments - cash flow hedges ​ 9,305 ​ — ​ 9,305 ​ — Total assets ​ $ 79,656 ​ $ 70,351 ​ $ 9,305 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Contingent consideration ​ $ 4,800 ​ $ — ​ $ — ​ $ 4,800 Derivative instruments - cash flow hedges ​ 2,046 ​ — ​ 2,046 ​ — Total liabilities ​ $ 6,846 ​ $ — ​ $ 2,046 ​ $ 4,800 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ value as of ​ Fair Value Measurements Using ​ ​ June 30, ​ Inputs Considered as ​ 2021 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Exchange traded securities (1) ​ $ 19,963 ​ $ 18,581 ​ $ 1,382 ​ $ — Certificates of deposit (2) ​ 12,500 ​ 12,500 ​ — ​ — Derivative instruments - cash flow hedges ​ 275 ​ — ​ 275 ​ — Total assets ​ $ 32,738 ​ $ 31,081 ​ $ 1,657 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Contingent consideration ​ $ 29,400 ​ $ — ​ $ — ​ $ 29,400 Derivative instruments - cash flow hedges ​ 8,376 ​ — ​ 8,376 ​ — Total liabilities ​ $ 37,776 ​ $ — ​ $ 8,376 ​ $ 29,400 ​ (1) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $6.6 million at both March 31, 2022 and June 30, 2021. The fair value of the Company’s investment in CCXI was $36.5 million and $20.0 million at March 31, 2022 and June 30, 2021, respectively. The Company exercised the warrant via net share settlement to acquire 66,833 additional shares of CCXI equity shares during the quarter ended March 31, 2022. The warrant was valued at $1.4 million as of June 30, 2021. The Company also purchased exchange traded investment grade bond funds during the quarter ended March 31, 2022. The cost basis and fair value of these exchange traded investment grade bond funds as of March 31, 2022 was $20.0 million and $19.4 million, respectively. (2) Included in available-for-sale investments on the balance sheet. The certificates of deposit have contractual maturity dates within one year. ​ Fair value measurements of available for sale securities Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level 2 Fair value measurements of derivative instruments In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount. The notional amount decreased by $100 million in October 2020, $80 million in October 2021 and will further decrease by $200 million in October 2022. In June 2020, the Company de-designated $80 million of the notional amount set to expire in October 2020. The net loss associated with the June 2020 de-designated portion of the derivative instrument was not reclassified into earnings based on the amount of probable variable interest payments to occur within a two-month time period of the forecasted hedged transaction. In December 2020, the Company de-designated an additional $80 million of notional amount set to expire in October 2021. The net loss associated with the December 2020 de-designated portion of the derivative instrument was recorded as a loss in other non-operating income related to variable interest debt payments in certain months on a portion of the de-designated derivative that was not expected to occur. The fair value of the designated derivative instrument is $2 million and is recorded within short-term liabilities on the Consolidated Balance Sheet as of March 31, 2022. The fair value of the designated derivative instrument was $7.6 million as of June 30, 2021 and was recorded within other long-term liabilities on the Consolidated Balance Sheet. In May 2021, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt. The forward starting swap reduces the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swap, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal amount. The effective date of the swap is November 2022 with the full swap maturing in November 2025. The fair value of the derivative instrument was $9.3 million and $0.3 million as of March 31, 2022 and June 30, 2021, respectively, which is recorded within other long-term assets on the Consolidated Balance Sheet. Changes in the fair value of the designated hedged instruments are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $5.2 million to interest expense and related tax benefits of $1.2 million during the nine months ended March 31, 2022. The Company reclassified $6.7 million to interest expense, $0.5 million to non-operating income for the portion of de-designated variable payments considered probable to not occur, and related tax benefits of $1.7 million during the nine months ended March 31, 2021.The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities. Fair value measurements of contingent consideration The Company has $4.8 million in contingent consideration recorded as of March 31, 2022, which is the fair value of contingent consideration related to the Asuragen acquisition. The Company is required to make contingent consideration payments of up to $105.0 million as part of the acquisition agreement. The contingent agreement is based on achieving certain revenue thresholds. The opening balance sheet fair value of the liabilities for the Asuragen acquisition was $18.3 million, as discussed in Note 4. The fair value amount recorded on the opening balance sheet of the revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. As of June 30, 2021, the Company had accrued contingent consideration for the Asuragen, B-Mogen Biotechnologies Inc, and QT Holdings Corporation acquisitions. During the first quarter of fiscal 2022 , . ​ The ultimate settlement of contingent consideration liabilities for the Asuragen acquisition could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense. The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ ​ 2022 ​ 2022 ​ ​ ​ ​ ​ ​ ​ Fair value at the beginning of period ​ $ 9,000 ​ $ 29,400 Change in fair value of contingent consideration ​ (4,200) ​ (20,600) Payments ​ — ​ (4,000) Fair value at the end of period ​ $ 4,800 ​ $ 4,800 ​ The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may incur impairment charges for securities in our investment portfolio. Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6. Debt and Other Financing Arrangements: On August 1, 2018, the Company entered into a new revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 12.5 basis points. The Credit Agreement matures on August 1, 2023 and contains customary restrictive and financial covenants and customary events of default. As of March 31, 2022, the outstanding balance under the Credit Agreement was $259.1 million.

Leases

Leases	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 7. Leases: As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techne’s incremental borrowing rate or, if available, the rate implicit in the lease. Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the nine months ended March 31, 2022, the Company recognized $3.4 million in variable lease expense and $10.8 million relating to fixed lease expense in the Condensed Consolidated Statements of Earnings and Comprehensive Income. The following table summarizes the balance sheet classification of the Company’s operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ ​ ​ ​ March 31, ​ ​ Balance Sheet Classification ​ 2022 Operating leases: ​ ​ ​ Operating lease right of use assets ​ Right of Use Asset ​ $ 63,450 ​ ​ ​ ​ ​ ​ ​ ​ ​ Current operating lease liabilities ​ Operating lease liabilities current ​ $ 11,864 ​ Noncurrent operating lease liabilities ​ Operating lease liabilities ​ 56,348 ​ Total operating lease liabilities ​ ​ ​ ​ $ 68,212 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ 6.98 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ 3.89 % ​ The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the nine months ended (in thousands): ​ ​ ​ ​ ​ ​ ​ Nine months ended ​ ​ March 31, ​ 2022 Cash amounts paid on operating lease liabilities ​ $ 11,221 ​ ​ ​ ​ Right of use assets obtained in exchange for lease liabilities ​ 2,812 ​ ​ The following table summarizes the fair value of the lease liability by payment date for the Company’s operating leases by fiscal year (in thousands): ​ ​ ​ ​ ​ ​ ​ Operating ​ ​ Leases Remainder of fiscal 2022 ​ $ 3,686 2023 ​ 13,874 2024 ​ 12,214 2025 ​ 11,057 2026 ​ 9,634 Thereafter ​ 27,819 Total ​ $ 78,284 Less: Amounts representing interest ​ 10,072 Total Lease obligations ​ $ 68,212 ​ Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options.

Supplemental Equity and Accumul

Supplemental Equity and Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	​ ​ Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss): Supplemental Equity The Company has declared cash dividends per share of $0.32 and $0.96 in both the three and nine months ended March 31, 2022 and 2021, respectively. Consolidated Changes in Equity (amounts in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bio-Techne Shareholders ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ Common Stock ​ Paid-in ​ Retained ​ Comprehensive ​ Noncontrolling ​ ​ ​ ​ ​ Shares ​ Amount ​ Capital ​ Earnings ​ Income(Loss) ​ Interest ​ Total Balances at June 30, 2021 38,955 ​ $ 390 ​ $ 534,411 ​ $ 1,085,461 ​ $ (57,291) ​ $ 8,263 ​ $ 1,571,234 Net earnings ​ ​ ​ ​ ​ ​ 69,615 ​ ​ ​ (634) ​ 68,981 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ (6,925) ​ (39) ​ (6,964) Share repurchases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common stock issued for exercise of options 295 ​ 3 ​ 36,345 ​ (13,481) ​ ​ ​ 22,867 Common stock issued for restricted stock awards 20 ​ 0 ​ 0 ​ (9,765) ​ ​ ​ (9,765) Cash dividends ​ ​ ​ ​ ​ ​ (12,493) ​ ​ ​ ​ (12,493) Stock-based compensation expense ​ ​ ​ ​ ​ 11,396 ​ ​ ​ ​ ​ 11,396 Common stock issued to employee stock purchase plan 3 ​ 0 ​ 1,358 ​ ​ ​ ​ ​ 1,358 Employee stock purchase plan expense ​ ​ ​ ​ ​ 341 ​ ​ ​ ​ ​ 341 Balances at September 30, 2021 39,273 ​ $ 393 ​ $ 583,851 ​ $ 1,119,337 ​ $ (64,216) ​ $ 7,590 ​ $ 1,646,955 Net earnings ​ ​ ​ ​ ​ ​ 80,173 ​ ​ ​ (8,114) ​ 72,059 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 4,742 ​ 66 ​ 4,808 Share repurchases (89) ​ (1) ​ ​ ​ (41,293) ​ ​ ​ (41,294) Common stock issued for exercise of options 134 ​ 1 ​ 18,604 ​ ​ ​ ​ ​ 18,605 Common stock issued for restricted stock awards 1 ​ ​ ​ ​ ​ ​ ​ ​ ​ — Cash dividends ​ ​ ​ ​ ​ ​ (12,576) ​ ​ ​ ​ (12,576) Stock-based compensation expense ​ ​ ​ ​ ​ 13,701 ​ ​ ​ ​ ​ 13,701 Common stock issued to employee stock purchase plan ​ ​ ​ ​ 6 ​ ​ ​ ​ ​ 6 Employee stock purchase plan expense ​ ​ ​ ​ ​ 267 ​ ​ ​ ​ ​ 267 Balances at December 31, 2021 39,319 ​ $ 393 ​ $ 616,429 ​ $ 1,145,641 ​ $ (59,474) ​ $ (458) ​ $ 1,702,531 Net earnings ​ ​ ​ ​ ​ ​ 60,739 ​ ​ ​ (595) ​ 60,144 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 4,329 ​ (1) ​ 4,328 Share repurchases (145) ​ (1) ​ ​ ​ (60,837) ​ ​ ​ (60,838) Common stock issued for exercise of options 84 ​ 1 ​ 10,494 ​ ​ ​ ​ ​ 10,495 Common stock issued for restricted stock awards 1 ​ ​ ​ ​ ​ (159) ​ ​ ​ (159) Cash dividends ​ ​ ​ ​ ​ ​ (12,577) ​ ​ ​ ​ (12,577) Stock-based compensation expense ​ ​ ​ ​ ​ 8,043 ​ ​ ​ ​ ​ 8,043 Common stock issued to employee stock purchase plan 4 ​ ​ ​ 1,330 ​ ​ ​ ​ ​ 1,330 Employee stock purchase plan expense ​ ​ ​ ​ ​ 25 ​ ​ ​ ​ ​ 25 Balances at March 31, 2022 39,263 ​ ​ 393 ​ ​ 636,321 ​ ​ 1,132,807 ​ ​ (55,145) ​ ​ (1,054) ​ ​ 1,713,322 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bio-Techne Shareholders ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ Common Stock ​ Paid-in ​ Retained ​ Comprehensive ​ Noncontrolling ​ ​ ​ ​ ​ Shares ​ Amount ​ Capital ​ Earnings ​ Income(Loss) ​ Interest ​ Total Balances at June 30, 2020 38,453 ​ $ 385 ​ $ 420,536 ​ $ 1,057,470 ​ $ (97,199) ​ $ — ​ $ 1,381,192 Cumulative effect adjustments due to adoption of new accounting standards ​ ​ ​ ​ ​ ​ (276) ​ ​ ​ ​ (276) Net earnings ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 33,395 ​ ​ ​ ​ ​ ​ ​ ​ 33,395 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 14,057 ​ ​ ​ 14,057 Common stock issued for exercise of options 117 ​ 1 ​ 13,727 ​ ​ ​ ​ ​ 13,728 Common stock issued for restricted stock awards 25 ​ 0 ​ (0) ​ (4,890) ​ ​ ​ (4,890) Cash dividends ​ ​ ​ ​ ​ ​ (12,336) ​ ​ ​ ​ (12,336) Stock-based compensation expense ​ ​ ​ ​ ​ 12,667 ​ ​ ​ ​ ​ 12,667 Common stock issued to employee stock purchase plan 6 ​ 0 ​ 1,463 ​ ​ ​ ​ ​ 1,463 Employee stock purchase plan expense ​ ​ ​ ​ ​ 286 ​ ​ ​ ​ ​ 286 Balances at September 30, 2020 38,601 ​ $ 386 ​ $ 448,679 ​ $ 1,073,362 ​ $ (83,142) ​ $ — ​ $ 1,439,285 Non-controlling interest in Eminence ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 8,985 ​ 8,985 Net earnings ​ ​ ​ ​ ​ ​ 46,274 ​ ​ ​ (130) ​ 46,144 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 18,904 ​ 83 ​ 18,987 Common stock issued for exercise of options 161 ​ 2 ​ 16,748 ​ (2,482) ​ ​ ​ 14,268 Common stock issued for restricted stock awards 3 ​ 0 ​ (0) ​ 0 ​ ​ ​ — Cash dividends ​ ​ ​ ​ ​ ​ (12,392) ​ ​ ​ ​ (12,392) Stock-based compensation expense ​ ​ ​ ​ ​ 15,471 ​ ​ ​ ​ ​ 15,471 Employee stock purchase plan expense ​ ​ ​ ​ ​ 106 ​ ​ ​ ​ ​ 106 Balances at December 31, 2020 38,765 ​ $ 388 ​ $ 481,004 ​ $ 1,104,762 ​ $ (64,238) ​ $ 8,938 ​ $ 1,530,854 Net earnings ​ ​ ​ ​ ​ ​ 45,782 ​ ​ ​ (380) ​ 45,402 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 215 ​ (69) ​ 146 Share repurchases ​ (120) ​ ​ (1) ​ ​ ​ ​ ​ (43,177) ​ ​ ​ ​ ​ ​ ​ ​ (43,178) Common stock issued for exercise of options 195 ​ 2 ​ 21,324 ​ (4,332) ​ ​ ​ 16,994 Common stock issued for restricted stock awards 10 ​ 0 ​ (0) ​ (1,801) ​ ​ ​ (1,801) Cash dividends ​ ​ ​ ​ ​ ​ (12,446) ​ ​ ​ ​ (12,446) Stock-based compensation expense ​ ​ ​ ​ ​ 10,232 ​ ​ ​ ​ ​ 10,232 Common stock issued to employee stock purchase plan ​ 4 ​ ​ 0 ​ ​ 1,328 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,328 Employee stock purchase plan expense ​ ​ ​ ​ ​ 411 ​ ​ ​ ​ ​ 411 Balances at March 31, 2021 38,854 ​ $ 389 ​ $ 514,299 ​ $ 1,088,788 ​ $ (64,023) ​ $ 8,489 ​ $ 1,547,942 ​ ​ ​ Accumulated Other Comprehensive Income The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The Company reclassified $4.0 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the nine months ended March 31, 2022. The Company reclassified $5.5 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the nine months ended March 31, 2021. The accumulated balances related to each component of other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ Gains ​ Foreign ​ ​ ​ ​ ​ (Losses) on ​ Currency ​ ​ ​ ​ ​ Derivative ​ Translation ​ ​ ​ ​ Instruments Adjustments Total Balance as of June 30, 2021 ​ $ (6,193) ​ $ (51,098) ​ $ (57,291) Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne ​ 7,757 ​ (9,599) ​ (1,842) Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (1) ​ 3,988 ​ $ — ​ $ 3,988 Balance as of March 31, 2022 (2) ​ $ 5,552 ​ ​ (60,697) ​ ​ (55,145) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ Gains ​ Foreign ​ ​ ​ ​ ​ (Losses) on ​ Currency ​ ​ ​ ​ ​ Derivative ​ Translation ​ ​ ​ ​ Instruments Adjustments Total Balance as of June 30, 2020 attributable to Bio-Techne ​ $ (13,253) ​ $ (83,946) ​ $ (97,199) Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne ​ (13) ​ 27,686 ​ 27,673 Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3) ​ 5,503 ​ — ​ 5,503 Balance as of March 31, 2021 (2) ​ $ (7,763) ​ $ (56,260) ​ $ (64,023) ​ (1) Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $5,214 to interest expense and recorded a related tax benefit of $1,226 during the nine months ended March 31, 2022. (2) The Company had a net deferred tax liability of $1,706 and a net deferred tax benefit of $2,394 included in the accumulated other comprehensive income loss as of March 31, 2022 and 2021, respectively. (3) Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,662 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur in the nine months ended March 31, 2021. The Company also recorded a related tax benefit of $1,670 during the nine months ended March 31, 2021.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9. Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Earnings per share – basic: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net earnings, including noncontrolling interest ​ $ 60,144 $ 45,402 ​ $ 201,184 $ 124,941 Less net earnings (loss) attributable to noncontrolling interest ​ ​ (595) ​ (380) ​ ​ (9,343) ​ (509) Net earnings attributable to Bio-Techne ​ $ 60,739 ​ $ 45,782 ​ $ 210,527 ​ $ 125,450 Income allocated to participating securities ​ (25) ​ (27) ​ (95) ​ (77) Income available to common shareholders ​ $ 60,714 ​ $ 45,755 ​ $ 210,432 ​ $ 125,373 Weighted-average shares outstanding – basic ​ 39,272 ​ 38,856 ​ 39,225 ​ 38,693 Earnings per share – basic ​ $ 1.55 ​ $ 1.18 ​ $ 5.36 ​ $ 3.24 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings per share – diluted: ​ ​ ​ ​ Net earnings, including noncontrolling interest ​ $ 60,144 ​ $ 45,402 ​ $ 201,184 ​ $ 124,941 Less net earnings (loss) attributable to noncontrolling interest ​ ​ (595) ​ ​ (380) ​ ​ (9,343) ​ ​ (509) Net earnings attributable to Bio-Techne ​ $ 60,739 ​ $ 45,782 ​ $ 210,527 ​ $ 125,450 Income allocated to participating securities ​ (25) ​ (27) ​ (95) ​ (77) Income available to common shareholders ​ $ 60,714 ​ $ 45,755 ​ $ 210,432 ​ $ 125,373 Weighted-average shares outstanding – basic ​ 39,272 ​ 38,856 ​ 39,225 ​ 38,693 Dilutive effect of stock options and restricted stock units ​ 1,697 ​ 1,820 ​ 1,848 ​ 1,612 Weighted-average common shares outstanding – diluted ​ 40,969 ​ 40,676 ​ 41,073 ​ 40,305 Earnings per share – diluted ​ $ 1.48 ​ $ 1.12 ​ $ 5.12 ​ $ 3.11 ​ The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.8 million and 1.8 million for the quarter ended March 31, 2022 and 2021 respectively and 0.7 million and 1.6 million for the nine months ended March 31, 2022 and 2021 respectively.

Share-based Compensation

Share-based Compensation	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 10. Share-based Compensation: During the nine months ended March 31, 2022 and 2021, the Company granted 0.3 million and 0.7 million stock options at weighted average grant prices of $480.67 and $269.64 and weighted average fair values of $119.10 and $57.50, respectively. During the nine months ended March 31, 2022 and 2021, the Company granted 27,573 and 23,367 restricted stock units at a weighted average fair value of $470.38 and $269.87, respectively. During the nine months ended March 31, 2022 and 2021, the Company granted 6,896 and 11,803 shares of restricted common stock shares at a weighted average fair value of $489.34 and $264.73. Stock options for 555,103 and 505,137 shares of common stock with total intrinsic values of $196.3 million and $108.0 million were exercised during the nine months ended March 31, 2022 and 2021, respectively. Stock-based compensation expense, inclusive of payroll taxes, of $8.7 million and $11.1 million was included in selling, general and administrative expenses for the quarter ended March 31, 2022 and 2021 respectively. Stock-based compensation expenses, inclusive of payroll taxes, of $35.9 million and $36.0 million was included in selling, general, and administrative expenses for the nine months ended March 31, 2022 and 2021, respectively. Additionally, the company recognized $0.4 million and $1.1 million of stock-based compensation costs in cost of goods sold in the quarter and nine months ended March 31, 2022 respectively, compared to $0.4 million and $1.5 million in cost of goods sold in the comparative prior year periods. As of March 31, 2022, there was $41.7 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years. In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded immaterial expense for the quarter ended March 31, 2022 and $0.4 million for the quarter ended March 31, 2021. The Company recorded expense of $0.6 million and $0.8 million for the ESPP for the nine months ended March 31, 2022 and 2021, respectively.

Other Income (Expense)

Other Income (Expense)	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	Note 11. Other Income / (Expense): ​ The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Interest expense ​ $ (2,493) ​ $ (2,660) ​ $ (8,804) ​ $ (10,661) Interest income ​ ​ 168 ​ ​ 114 ​ ​ 606 ​ ​ 306 Other non-operating income (expense), net (1) ​ (19,350) ​ (20,726) ​ 14,515 ​ (17,297) Total other income (expense) ​ $ (21,675) ​ $ (23,272) ​ $ 6,317 ​ $ (27,652) ​ (1) Primarily due to a $17.2 million loss and $16.5 million gain in the fair value of our CCXI investment for the quarter and nine months ended March 31, 2022, respectively, as compared to a $16.6 million loss and $10.2 million loss in the comparative periods.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 12. Income Taxes: The Company’s effective income tax rate for the third quarter of fiscal 2022 and 2021 was 12.5% and (0.1)%, respectively, of consolidated earnings before income taxes, and 9.5% and 11.4% for the first nine months of fiscal 2022 and 2021, respectively. The change in the company’s tax rate for the quarter and nine months ended March 31, 2022 compared to the quarter and nine months ended March 31, 2021 was driven by discrete tax items. The Company recognized total net benefits related to discrete tax items of $6.3 million and $31.6 million during the quarter and nine months ended March 31, 2022, respectively, compared to $11.6 million and $19.5 million during the quarter and nine months ended March 31, 2021, respectively. Share-based compensation excess tax benefit contributed $3.4 million and $27.8 million in the quarter and nine months ended March 31, 2022, respectively, compared to $11.7 million and $19.7 million in the quarter and nine months, ended March 31, 2021, respectively. The Company recognized total other immaterial net discrete tax benefit of $2.9 million and $3.8 million in the quarter and nine months ended March 31, 2022, respectively, compared to $0.1 million and $0.2 million of other immaterial net discrete tax expense in the quarter and nine months ended March 31, 2021, respectively.

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 13. Segment Information: The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Net sales: ​ ​ ​ ​ ​ ​ ​ ​ ​ Protein Sciences ​ $ 213,176 $ 185,623 ​ $ 615,332 $ 512,248 Diagnostics and Genomics ​ 77,679 ​ 58,093 ​ 203,191 ​ 160,687 Intersegment ​ (479) ​ (164) ​ (1,152) ​ (931) Consolidated net sales ​ $ 290,376 $ 243,552 ​ $ 817,371 $ 672,004 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income: ​ ​ ​ ​ Protein Sciences ​ $ 96,750 $ 88,983 ​ $ 280,131 $ 239,788 Diagnostics and Genomics ​ 19,405 ​ 10,417 ​ 37,748 ​ 27,197 Segment operating income ​ $ 116,155 ​ $ 99,400 ​ $ 317,879 ​ $ 266,985 Costs recognized on sale of acquired inventory ​ — ​ (68) ​ (1,596) ​ (91) Amortization of acquisition related intangible assets ​ (18,173) ​ (15,222) ​ (54,942) ​ (45,750) Impact of partially owned consolidated subsidiaries (1) ​ (892) ​ (699) ​ (3,446) ​ (906) Acquisition related expenses ​ 3,710 ​ (1,731) ​ 19,328 ​ (6,289) Eminence impairment ​ ​ — ​ ​ — ​ ​ (18,715) ​ ​ — Stock based compensation, inclusive of employer taxes ​ (9,056) ​ (11,968) ​ (37,731) ​ (41,525) Restructuring costs ​ 291 ​ — ​ (1,638) ​ (142) Corporate general, selling, and administrative expenses ​ (1,588) ​ (1,086) ​ (3,122) ​ (3,568) Consolidated operating income ​ $ 90,447 $ 68,626 ​ $ 216,017 $ 168,714 ​ (1) Adjusted operating income for the third quarter and full year of fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially owned consolidated subsidiaries on the Company’s adjusted operating income.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 14. Subsequent Events: None.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2022
Policy Text Block [Abstract]
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill: Given the upcoming liquidation process to dispose of the Eminence assets, the Company identified a triggering event and performed impairment testing during the second quarter of fiscal 2022. The impairment testing resulted in a full impairment of the Eminence goodwill and intangible assets, which resulted in charges of $8.3 million and $8.6 million, respectively, for the nine-months ended March 31, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. The Company recorded the impairment charges within the General and Administrative line in the Consolidated Income Statement. The impairment charges recorded within Net Earnings Attributable to Bio-Techne were reduced by approximately $8 million recorded within Net Earnings Attributable to Noncontrolling Interests. The remaining net tangible assets of Eminence included in our Consolidated Balance Sheet as of March 31, 2022, were approximately $4 million and primarily consisted of fixed assets and related deposits of $3.8 million, inventory of $0.8 million, receivables of $0.7 million, and other current assets of $0.2 million. The Company also had $2.2 million related to current liabilities. The Company holds a financial interest of approximately 57.4% in those tangible assets in the upcoming liquidation process.
Investment, Policy [Policy Text Block]	Investments The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in annual earnings before interest, taxes, depreciation, and amortization (EBITDA) at any point prior to December 31, 2027. Once triggered, the Company is required to make a payment of $231 million in exchange for a 19.9% ownership stake. If Wilson Wolf doesn’t achieve the revenue and EBITDA targets by December 31, 2027, the agreement will expire. Once the first part of the forward contract is triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. The approximate multiple for total expected payments of the second forward contract is 4.4 times the annual revenue of Wilson Wolf. The Company has elected to apply the measurement alternative as detailed under ASC 321-10-35-2 for the Wilson Wolf investment. The Company recorded the $25 million payment as a cost basis investment within Other long-term assets on the Consolidated Balance Sheet.
Restructuring Actions [Policy Text Block]	Restructuring actions In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were substantially complete as of the end of the third fiscal quarter, with final remaining payouts expected to occur in the fourth quarter of fiscal 2022. As a result of the restructuring activities, an estimated pre-tax charge of $1.2 million was recorded within our Diagnostics and Genomics segment during the first quarter of fiscal 2022. Additional charges of approximately $0.5 million and $(0.3) million were recorded in the second and third quarters of fiscal 2022, respectively. These additional charges related to the refinement of our estimated close down costs as well as miscellaneous shut-down costs incurred during the quarter. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the nine months ended March 31, 2022 were recorded within operating income on the income statement as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Employee ​ Asset ​ ​ ​ Severance Impairment and other Total Selling, general and administrative ​ $ 649 ​ $ 750 ​ $ 1,399 ​ Restructuring actions, including cash and non-cash impacts, are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Employee ​ Asset ​ ​ ​ Severance Impairment and other Total Accrued restructuring action balances as of September 30, 2021 (1) ​ $ 639 ​ $ 364 ​ $ 1,003 Incremental expense incurred in the second quarter of fiscal 2022 ​ ​ — ​ ​ 242 ​ ​ 242 Cash payments ​ ​ (370) ​ ​ (242) ​ ​ (612) Adjustments ​ ​ 301 ​ ​ (37) ​ ​ 264 Accrued restructuring actions balances as of December 31, 2021 ​ ​ 570 ​ ​ 327 ​ ​ 897 Cash payments ​ ​ (200) ​ ​ (272) ​ ​ (472) Adjustments (2) ​ ​ (345) ​ ​ (28) ​ ​ (373) Accrued restructuring actions balances as of March 31, 2022 ​ $ 25 ​ $ 27 ​ $ 52 ​ (1) The expense recorded for the three months ended September 30, 2021 of $1.2 million included $0.2 million related to the non-cash impairment of fixed assets. (2) During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This charge is recorded within Other current liabilities as of March 31, 2022. There were no cash payments or adjustments related to this restructuring during the quarter ended March 31, 2022.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements There were no accounting pronouncements adopted in the nine months ended March 31, 2022. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2021.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Restructuring and Related Costs [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Employee ​ Asset ​ ​ ​ Severance Impairment and other Total Selling, general and administrative ​ $ 649 ​ $ 750 ​ $ 1,399 ​ Restructuring actions, including cash and non-cash impacts, are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Employee ​ Asset ​ ​ ​ Severance Impairment and other Total Accrued restructuring action balances as of September 30, 2021 (1) ​ $ 639 ​ $ 364 ​ $ 1,003 Incremental expense incurred in the second quarter of fiscal 2022 ​ ​ — ​ ​ 242 ​ ​ 242 Cash payments ​ ​ (370) ​ ​ (242) ​ ​ (612) Adjustments ​ ​ 301 ​ ​ (37) ​ ​ 264 Accrued restructuring actions balances as of December 31, 2021 ​ ​ 570 ​ ​ 327 ​ ​ 897 Cash payments ​ ​ (200) ​ ​ (272) ​ ​ (472) Adjustments (2) ​ ​ (345) ​ ​ (28) ​ ​ (373) Accrued restructuring actions balances as of March 31, 2022 ​ $ 25 ​ $ 27 ​ $ 52 ​ (1) The expense recorded for the three months ended September 30, 2021 of $1.2 million included $0.2 million related to the non-cash impairment of fixed assets. (2)

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Revenue by type is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Consumables ​ $ 239,171 ​ $ 198,818 ​ $ 657,568 ​ $ 542,909 Instruments ​ 28,899 ​ 24,748 ​ 92,121 ​ 70,849 Services ​ 17,815 ​ 14,503 ​ 51,426 ​ 45,142 Total product and services revenue, net ​ $ 285,885 ​ $ 238,069 ​ $ 801,115 ​ $ 658,900 Royalty revenues ​ 4,491 ​ 5,483 ​ 16,256 ​ 13,104 Total revenues, net ​ $ 290,376 ​ $ 243,552 ​ $ 817,371 ​ $ 672,004 ​ Revenue by geography is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 United States ​ $ 163,976 ​ $ 131,586 ​ $ 447,045 ​ $ 359,586 EMEA, excluding United Kingdom ​ 55,301 ​ 54,552 ​ 164,003 ​ 147,622 United Kingdom ​ 12,920 ​ 11,213 ​ 37,240 ​ 29,599 APAC, excluding Greater China ​ 21,100 ​ 19,002 ​ 58,204 ​ 52,744 Greater China ​ 26,554 ​ 20,467 ​ 85,997 ​ 63,685 Rest of World ​ 10,525 ​ 6,732 ​ 24,882 ​ 18,768 Net Sales ​ $ 290,376 ​ $ 243,552 ​ $ 817,371 ​ $ 672,004

Selected Balance Sheet Data (Ta

Selected Balance Sheet Data (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Inventories consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ 2022 2021 Raw materials ​ $ 69,263 ​ $ 55,096 Finished goods (1) ​ 64,742 ​ 67,108 Inventories, net ​ $ 134,005 ​ $ 122,204 ​ (1) Finished goods inventory of $5,722 and $5,456 included within other long-term assets in the respective March 31, 2022 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.
Property, Plant and Equipment [Table Text Block]	Property and equipment consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ 2022 2021 Land ​ $ 8,603 ​ $ 8,612 Buildings and improvements ​ 225,378 ​ 190,661 Machinery and equipment ​ ​ 164,665 ​ ​ 149,410 Construction in progress ​ 26,508 ​ 49,073 Property and equipment, cost ​ 425,154 ​ 397,756 Accumulated depreciation and amortization ​ (206,756) ​ (189,849) Property and equipment, net ​ $ 218,398 ​ $ 207,907
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible assets consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ Developed technology ​ $ 543,977 ​ $ 552,160 Trade names ​ 147,311 ​ 147,640 Customer relationships ​ 228,943 ​ 232,493 Patents ​ 3,249 ​ 2,926 Other intangibles ​ 6,313 ​ 6,316 Definite-lived intangible assets ​ 929,793 ​ 941,535 Accumulated amortization ​ (401,151) ​ (348,267) Definite-lived intangibles assets, net ​ 528,642 ​ 593,268 In process research and development ​ 22,700 ​ 22,700 Total intangible assets, net ​ $ 551,342 ​ $ 615,968
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Changes to the carrying amount of net intangible assets for the period ended March 31, 2022 consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Beginning balance ​ $ 615,968 Acquisitions ​ — Other additions ​ 283 Amortization expense ​ (55,731) Currency translation ​ (615) Eminence impairment (1) ​ ​ (8,563) Ending balance ​ $ 551,342
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The estimated future amortization expense for intangible assets as of March 31, 2022 is as follows (in thousands): ​ ​ ​ ​ ​ 2022 remainder $ 18,478 2023 ​ 71,725 2024 ​ 68,857 2025 ​ 65,621 2026 ​ 61,876 Thereafter ​ 242,085 Total ​ $ 528,642 ​ (1) As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22.
Schedule of Goodwill [Table Text Block]	Changes to the carrying amount of goodwill for the period ended March 31, 2022 consist of (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics and ​ ​ ​ Protein Sciences ​ Genomics ​ Total Beginning balance ​ $ 392,717 ​ $ 450,350 ​ $ 843,067 Acquisitions (1) ​ — ​ (4,407) ​ (4,407) Eminence impairment ​ ​ (8,275) ​ ​ — ​ ​ (8,275) Currency translation ​ (2,588) ​ (179) ​ (2,767) Ending balance ​ $ 381,854 ​ $ 445,764 ​ $ 827,618

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preliminary allocation at ​ Adjustments Final allocation at ​ acquisition date ​ to fair value ​ March 31, 2022 Current assets, net of cash $ 10,422 ​ $ ​ ​ $ 10,422 Equipment and other long-term assets 3,762 ​ ​ ​ ​ 3,762 Intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ Developed technology 107,000 ​ ​ ​ ​ 107,000 In-process research and development 22,700 ​ ​ ​ ​ 22,700 Customer relationships 11,700 ​ ​ ​ ​ 11,700 Trade names 2,000 ​ ​ ​ ​ 2,000 Non-competition agreement 1,000 ​ ​ ​ ​ 1,000 Goodwill 94,970 ​ ​ (4,407) ​ 90,563 Total assets acquired 253,554 ​ ​ (4,407) ​ 249,147 ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities 4,003 ​ ​ 960 ​ 4,963 Deferred income taxes, net 15,664 ​ ​ (5,367) ​ 10,297 Net assets acquired $ 233,887 ​ $ — ​ $ 233,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash paid, net of cash acquired 215,587 ​ ​ ​ ​ 215,587 Contingent consideration payable 18,300 ​ ​ ​ ​ 18,300 Net assets acquired $ 233,887 ​ $ — ​ $ 233,887

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ value as of ​ Fair Value Measurements Using ​ ​ March 31, ​ Inputs Considered as ​ ​ 2022 ​ Level 1 ​ Level 2 ​ Level 3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Exchange traded securities (1) ​ $ 55,851 ​ $ 55,851 ​ $ — ​ $ — Certificates of deposit (2) ​ 14,500 ​ 14,500 ​ — ​ — Derivative instruments - cash flow hedges ​ 9,305 ​ — ​ 9,305 ​ — Total assets ​ $ 79,656 ​ $ 70,351 ​ $ 9,305 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Contingent consideration ​ $ 4,800 ​ $ — ​ $ — ​ $ 4,800 Derivative instruments - cash flow hedges ​ 2,046 ​ — ​ 2,046 ​ — Total liabilities ​ $ 6,846 ​ $ — ​ $ 2,046 ​ $ 4,800 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ value as of ​ Fair Value Measurements Using ​ ​ June 30, ​ Inputs Considered as ​ 2021 Level 1 Level 2 Level 3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Exchange traded securities (1) ​ $ 19,963 ​ $ 18,581 ​ $ 1,382 ​ $ — Certificates of deposit (2) ​ 12,500 ​ 12,500 ​ — ​ — Derivative instruments - cash flow hedges ​ 275 ​ — ​ 275 ​ — Total assets ​ $ 32,738 ​ $ 31,081 ​ $ 1,657 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Contingent consideration ​ $ 29,400 ​ $ — ​ $ — ​ $ 29,400 Derivative instruments - cash flow hedges ​ 8,376 ​ — ​ 8,376 ​ — Total liabilities ​ $ 37,776 ​ $ — ​ $ 8,376 ​ $ 29,400 ​ (1) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $6.6 million at both March 31, 2022 and June 30, 2021. The fair value of the Company’s investment in CCXI was $36.5 million and $20.0 million at March 31, 2022 and June 30, 2021, respectively. The Company exercised the warrant via net share settlement to acquire 66,833 additional shares of CCXI equity shares during the quarter ended March 31, 2022. The warrant was valued at $1.4 million as of June 30, 2021. The Company also purchased exchange traded investment grade bond funds during the quarter ended March 31, 2022. The cost basis and fair value of these exchange traded investment grade bond funds as of March 31, 2022 was $20.0 million and $19.4 million, respectively. (2) Included in available-for-sale investments on the balance sheet. The certificates of deposit have contractual maturity dates within one year.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ ​ 2022 ​ 2022 ​ ​ ​ ​ ​ ​ ​ Fair value at the beginning of period ​ $ 9,000 ​ $ 29,400 Change in fair value of contingent consideration ​ (4,200) ​ (20,600) Payments ​ — ​ (4,000) Fair value at the end of period ​ $ 4,800 ​ $ 4,800 ​

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Lessee, Operating Lease, Asset and Liabilities [Table Text Block]	The following table summarizes the balance sheet classification of the Company’s operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ ​ ​ ​ March 31, ​ ​ Balance Sheet Classification ​ 2022 Operating leases: ​ ​ ​ Operating lease right of use assets ​ Right of Use Asset ​ $ 63,450 ​ ​ ​ ​ ​ ​ ​ ​ ​ Current operating lease liabilities ​ Operating lease liabilities current ​ $ 11,864 ​ Noncurrent operating lease liabilities ​ Operating lease liabilities ​ 56,348 ​ Total operating lease liabilities ​ ​ ​ ​ $ 68,212 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ 6.98 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ 3.89 %
Lessee, Operating Lease, Cash Flow Information [Table Text Block]	The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the nine months ended (in thousands): ​ ​ ​ ​ ​ ​ ​ Nine months ended ​ ​ March 31, ​ 2022 Cash amounts paid on operating lease liabilities ​ $ 11,221 ​ ​ ​ ​ Right of use assets obtained in exchange for lease liabilities ​ 2,812 ​
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	​ The following table summarizes the fair value of the lease liability by payment date for the Company’s operating leases by fiscal year (in thousands): ​ ​ ​ ​ ​ ​ ​ Operating ​ ​ Leases Remainder of fiscal 2022 ​ $ 3,686 2023 ​ 13,874 2024 ​ 12,214 2025 ​ 11,057 2026 ​ 9,634 Thereafter ​ 27,819 Total ​ $ 78,284 Less: Amounts representing interest ​ 10,072 Total Lease obligations ​ $ 68,212 ​

Supplemental Equity and Accum_2

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bio-Techne Shareholders ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ Common Stock ​ Paid-in ​ Retained ​ Comprehensive ​ Noncontrolling ​ ​ ​ ​ ​ Shares ​ Amount ​ Capital ​ Earnings ​ Income(Loss) ​ Interest ​ Total Balances at June 30, 2021 38,955 ​ $ 390 ​ $ 534,411 ​ $ 1,085,461 ​ $ (57,291) ​ $ 8,263 ​ $ 1,571,234 Net earnings ​ ​ ​ ​ ​ ​ 69,615 ​ ​ ​ (634) ​ 68,981 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ (6,925) ​ (39) ​ (6,964) Share repurchases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common stock issued for exercise of options 295 ​ 3 ​ 36,345 ​ (13,481) ​ ​ ​ 22,867 Common stock issued for restricted stock awards 20 ​ 0 ​ 0 ​ (9,765) ​ ​ ​ (9,765) Cash dividends ​ ​ ​ ​ ​ ​ (12,493) ​ ​ ​ ​ (12,493) Stock-based compensation expense ​ ​ ​ ​ ​ 11,396 ​ ​ ​ ​ ​ 11,396 Common stock issued to employee stock purchase plan 3 ​ 0 ​ 1,358 ​ ​ ​ ​ ​ 1,358 Employee stock purchase plan expense ​ ​ ​ ​ ​ 341 ​ ​ ​ ​ ​ 341 Balances at September 30, 2021 39,273 ​ $ 393 ​ $ 583,851 ​ $ 1,119,337 ​ $ (64,216) ​ $ 7,590 ​ $ 1,646,955 Net earnings ​ ​ ​ ​ ​ ​ 80,173 ​ ​ ​ (8,114) ​ 72,059 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 4,742 ​ 66 ​ 4,808 Share repurchases (89) ​ (1) ​ ​ ​ (41,293) ​ ​ ​ (41,294) Common stock issued for exercise of options 134 ​ 1 ​ 18,604 ​ ​ ​ ​ ​ 18,605 Common stock issued for restricted stock awards 1 ​ ​ ​ ​ ​ ​ ​ ​ ​ — Cash dividends ​ ​ ​ ​ ​ ​ (12,576) ​ ​ ​ ​ (12,576) Stock-based compensation expense ​ ​ ​ ​ ​ 13,701 ​ ​ ​ ​ ​ 13,701 Common stock issued to employee stock purchase plan ​ ​ ​ ​ 6 ​ ​ ​ ​ ​ 6 Employee stock purchase plan expense ​ ​ ​ ​ ​ 267 ​ ​ ​ ​ ​ 267 Balances at December 31, 2021 39,319 ​ $ 393 ​ $ 616,429 ​ $ 1,145,641 ​ $ (59,474) ​ $ (458) ​ $ 1,702,531 Net earnings ​ ​ ​ ​ ​ ​ 60,739 ​ ​ ​ (595) ​ 60,144 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 4,329 ​ (1) ​ 4,328 Share repurchases (145) ​ (1) ​ ​ ​ (60,837) ​ ​ ​ (60,838) Common stock issued for exercise of options 84 ​ 1 ​ 10,494 ​ ​ ​ ​ ​ 10,495 Common stock issued for restricted stock awards 1 ​ ​ ​ ​ ​ (159) ​ ​ ​ (159) Cash dividends ​ ​ ​ ​ ​ ​ (12,577) ​ ​ ​ ​ (12,577) Stock-based compensation expense ​ ​ ​ ​ ​ 8,043 ​ ​ ​ ​ ​ 8,043 Common stock issued to employee stock purchase plan 4 ​ ​ ​ 1,330 ​ ​ ​ ​ ​ 1,330 Employee stock purchase plan expense ​ ​ ​ ​ ​ 25 ​ ​ ​ ​ ​ 25 Balances at March 31, 2022 39,263 ​ ​ 393 ​ ​ 636,321 ​ ​ 1,132,807 ​ ​ (55,145) ​ ​ (1,054) ​ ​ 1,713,322 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bio-Techne Shareholders ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ Common Stock ​ Paid-in ​ Retained ​ Comprehensive ​ Noncontrolling ​ ​ ​ ​ ​ Shares ​ Amount ​ Capital ​ Earnings ​ Income(Loss) ​ Interest ​ Total Balances at June 30, 2020 38,453 ​ $ 385 ​ $ 420,536 ​ $ 1,057,470 ​ $ (97,199) ​ $ — ​ $ 1,381,192 Cumulative effect adjustments due to adoption of new accounting standards ​ ​ ​ ​ ​ ​ (276) ​ ​ ​ ​ (276) Net earnings ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 33,395 ​ ​ ​ ​ ​ ​ ​ ​ 33,395 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 14,057 ​ ​ ​ 14,057 Common stock issued for exercise of options 117 ​ 1 ​ 13,727 ​ ​ ​ ​ ​ 13,728 Common stock issued for restricted stock awards 25 ​ 0 ​ (0) ​ (4,890) ​ ​ ​ (4,890) Cash dividends ​ ​ ​ ​ ​ ​ (12,336) ​ ​ ​ ​ (12,336) Stock-based compensation expense ​ ​ ​ ​ ​ 12,667 ​ ​ ​ ​ ​ 12,667 Common stock issued to employee stock purchase plan 6 ​ 0 ​ 1,463 ​ ​ ​ ​ ​ 1,463 Employee stock purchase plan expense ​ ​ ​ ​ ​ 286 ​ ​ ​ ​ ​ 286 Balances at September 30, 2020 38,601 ​ $ 386 ​ $ 448,679 ​ $ 1,073,362 ​ $ (83,142) ​ $ — ​ $ 1,439,285 Non-controlling interest in Eminence ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 8,985 ​ 8,985 Net earnings ​ ​ ​ ​ ​ ​ 46,274 ​ ​ ​ (130) ​ 46,144 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 18,904 ​ 83 ​ 18,987 Common stock issued for exercise of options 161 ​ 2 ​ 16,748 ​ (2,482) ​ ​ ​ 14,268 Common stock issued for restricted stock awards 3 ​ 0 ​ (0) ​ 0 ​ ​ ​ — Cash dividends ​ ​ ​ ​ ​ ​ (12,392) ​ ​ ​ ​ (12,392) Stock-based compensation expense ​ ​ ​ ​ ​ 15,471 ​ ​ ​ ​ ​ 15,471 Employee stock purchase plan expense ​ ​ ​ ​ ​ 106 ​ ​ ​ ​ ​ 106 Balances at December 31, 2020 38,765 ​ $ 388 ​ $ 481,004 ​ $ 1,104,762 ​ $ (64,238) ​ $ 8,938 ​ $ 1,530,854 Net earnings ​ ​ ​ ​ ​ ​ 45,782 ​ ​ ​ (380) ​ 45,402 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ ​ 215 ​ (69) ​ 146 Share repurchases ​ (120) ​ ​ (1) ​ ​ ​ ​ ​ (43,177) ​ ​ ​ ​ ​ ​ ​ ​ (43,178) Common stock issued for exercise of options 195 ​ 2 ​ 21,324 ​ (4,332) ​ ​ ​ 16,994 Common stock issued for restricted stock awards 10 ​ 0 ​ (0) ​ (1,801) ​ ​ ​ (1,801) Cash dividends ​ ​ ​ ​ ​ ​ (12,446) ​ ​ ​ ​ (12,446) Stock-based compensation expense ​ ​ ​ ​ ​ 10,232 ​ ​ ​ ​ ​ 10,232 Common stock issued to employee stock purchase plan ​ 4 ​ ​ 0 ​ ​ 1,328 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,328 Employee stock purchase plan expense ​ ​ ​ ​ ​ 411 ​ ​ ​ ​ ​ 411 Balances at March 31, 2021 38,854 ​ $ 389 ​ $ 514,299 ​ $ 1,088,788 ​ $ (64,023) ​ $ 8,489 ​ $ 1,547,942
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ Gains ​ Foreign ​ ​ ​ ​ ​ (Losses) on ​ Currency ​ ​ ​ ​ ​ Derivative ​ Translation ​ ​ ​ ​ Instruments Adjustments Total Balance as of June 30, 2021 ​ $ (6,193) ​ $ (51,098) ​ $ (57,291) Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne ​ 7,757 ​ (9,599) ​ (1,842) Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (1) ​ 3,988 ​ $ — ​ $ 3,988 Balance as of March 31, 2022 (2) ​ $ 5,552 ​ ​ (60,697) ​ ​ (55,145) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ ​ ​ ​ ​ ​ ​ Gains ​ Foreign ​ ​ ​ ​ ​ (Losses) on ​ Currency ​ ​ ​ ​ ​ Derivative ​ Translation ​ ​ ​ ​ Instruments Adjustments Total Balance as of June 30, 2020 attributable to Bio-Techne ​ $ (13,253) ​ $ (83,946) ​ $ (97,199) Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne ​ (13) ​ 27,686 ​ 27,673 Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3) ​ 5,503 ​ — ​ 5,503 Balance as of March 31, 2021 (2) ​ $ (7,763) ​ $ (56,260) ​ $ (64,023) ​ (1) Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $5,214 to interest expense and recorded a related tax benefit of $1,226 during the nine months ended March 31, 2022. (2) The Company had a net deferred tax liability of $1,706 and a net deferred tax benefit of $2,394 included in the accumulated other comprehensive income loss as of March 31, 2022 and 2021, respectively. (3) Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,662 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur in the nine months ended March 31, 2021. The Company also recorded a related tax benefit of $1,670 during the nine months ended March 31, 2021.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Earnings per share – basic: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net earnings, including noncontrolling interest ​ $ 60,144 $ 45,402 ​ $ 201,184 $ 124,941 Less net earnings (loss) attributable to noncontrolling interest ​ ​ (595) ​ (380) ​ ​ (9,343) ​ (509) Net earnings attributable to Bio-Techne ​ $ 60,739 ​ $ 45,782 ​ $ 210,527 ​ $ 125,450 Income allocated to participating securities ​ (25) ​ (27) ​ (95) ​ (77) Income available to common shareholders ​ $ 60,714 ​ $ 45,755 ​ $ 210,432 ​ $ 125,373 Weighted-average shares outstanding – basic ​ 39,272 ​ 38,856 ​ 39,225 ​ 38,693 Earnings per share – basic ​ $ 1.55 ​ $ 1.18 ​ $ 5.36 ​ $ 3.24 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings per share – diluted: ​ ​ ​ ​ Net earnings, including noncontrolling interest ​ $ 60,144 ​ $ 45,402 ​ $ 201,184 ​ $ 124,941 Less net earnings (loss) attributable to noncontrolling interest ​ ​ (595) ​ ​ (380) ​ ​ (9,343) ​ ​ (509) Net earnings attributable to Bio-Techne ​ $ 60,739 ​ $ 45,782 ​ $ 210,527 ​ $ 125,450 Income allocated to participating securities ​ (25) ​ (27) ​ (95) ​ (77) Income available to common shareholders ​ $ 60,714 ​ $ 45,755 ​ $ 210,432 ​ $ 125,373 Weighted-average shares outstanding – basic ​ 39,272 ​ 38,856 ​ 39,225 ​ 38,693 Dilutive effect of stock options and restricted stock units ​ 1,697 ​ 1,820 ​ 1,848 ​ 1,612 Weighted-average common shares outstanding – diluted ​ 40,969 ​ 40,676 ​ 41,073 ​ 40,305 Earnings per share – diluted ​ $ 1.48 ​ $ 1.12 ​ $ 5.12 ​ $ 3.11

Other Income (Expense) (Tables)

Other Income (Expense) (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Interest expense ​ $ (2,493) ​ $ (2,660) ​ $ (8,804) ​ $ (10,661) Interest income ​ ​ 168 ​ ​ 114 ​ ​ 606 ​ ​ 306 Other non-operating income (expense), net (1) ​ (19,350) ​ (20,726) ​ 14,515 ​ (17,297) Total other income (expense) ​ $ (21,675) ​ $ (23,272) ​ $ 6,317 ​ $ (27,652) ​ (1) Primarily due to a $17.2 million loss and $16.5 million gain in the fair value of our CCXI investment for the quarter and nine months ended March 31, 2022, respectively, as compared to a $16.6 million loss and $10.2 million loss in the comparative periods.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following is financial information relating to the Company's reportable segments (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarter Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 Net sales: ​ ​ ​ ​ ​ ​ ​ ​ ​ Protein Sciences ​ $ 213,176 $ 185,623 ​ $ 615,332 $ 512,248 Diagnostics and Genomics ​ 77,679 ​ 58,093 ​ 203,191 ​ 160,687 Intersegment ​ (479) ​ (164) ​ (1,152) ​ (931) Consolidated net sales ​ $ 290,376 $ 243,552 ​ $ 817,371 $ 672,004 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income: ​ ​ ​ ​ Protein Sciences ​ $ 96,750 $ 88,983 ​ $ 280,131 $ 239,788 Diagnostics and Genomics ​ 19,405 ​ 10,417 ​ 37,748 ​ 27,197 Segment operating income ​ $ 116,155 ​ $ 99,400 ​ $ 317,879 ​ $ 266,985 Costs recognized on sale of acquired inventory ​ — ​ (68) ​ (1,596) ​ (91) Amortization of acquisition related intangible assets ​ (18,173) ​ (15,222) ​ (54,942) ​ (45,750) Impact of partially owned consolidated subsidiaries (1) ​ (892) ​ (699) ​ (3,446) ​ (906) Acquisition related expenses ​ 3,710 ​ (1,731) ​ 19,328 ​ (6,289) Eminence impairment ​ ​ — ​ ​ — ​ ​ (18,715) ​ ​ — Stock based compensation, inclusive of employer taxes ​ (9,056) ​ (11,968) ​ (37,731) ​ (41,525) Restructuring costs ​ 291 ​ — ​ (1,638) ​ (142) Corporate general, selling, and administrative expenses ​ (1,588) ​ (1,086) ​ (3,122) ​ (3,568) Consolidated operating income ​ $ 90,447 $ 68,626 ​ $ 216,017 $ 168,714 ​ (1) Adjusted operating income for the third quarter and full year of fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially owned consolidated subsidiaries on the Company’s adjusted operating income.

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Mar. 31, 2022USD ($)segment
Number of Operating Segments | segment							2
Goodwill, Impairment Loss					$ 8,300
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				$ 8,563	8,600
Restructuring Charges, Total					242
Payments for Restructuring				472	612
Asset Impairment [Member]
Asset Impairment Charges, Total						$ 1,200
Restructuring Charges, Total					242
Impairment of Long-Lived Assets to be Disposed of						$ 200
Payments for Restructuring				272	242
Employee Severance on Relocation of US Plant [Member]
Restructuring Charges, Total					200
Payments for Restructuring							$ 0
Diagnostics and Genomics [Member]
Restructuring Charges, Total			$ 1,200	(300)	$ 500
Wilson Wolf Corporation [Member]
Payments to Acquire Investments, Total	$ 25,000	$ 25,000
Wilson Wolf Corporation [Member] | First Part of Forward Contract [Member]
Forward Contract, Milestone, Annual Revenue Required	92,000			92,000			92,000
Forward Contract, Milestone, Annual EBITDA	55,000			55,000			55,000
Forward Contract Payment	$ 231,000			$ 231,000			$ 231,000
Wilson Wolf Corporation [Member] | First Part of Forward Contract Triggered [Member]
Noncontrolling Interest, Ownership Percentage by Parent	19.90%			19.90%			19.90%
Wilson Wolf Corporation [Member] | Second Part of Forward Contract [Member]
Forward Contract, Milestone, Annual Revenue Required	$ 226,000			$ 226,000			$ 226,000
Forward Contract, Milestone, Annual EBITDA	136,000			136,000			136,000
Forward Contract, Additional Investment	$ 1,000			$ 1,000			$ 1,000
Forward Contract, Milestone, Multiple for Total Expected Payments	4.4			4.4			4.4
Eminence Disposition [Member]
Goodwill, Impairment Loss							$ 8,300
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)							8,600
Inventory Write-down							900
Asset Impairment Charges, Total							900
Income (Loss) From Non-controlling Interest, Attributable to Parent							(8,000)
Total Assets of Impaired Asset Group	$ 4,000			$ 4,000			4,000
Inventory of Impaired Asset Group	800			800			800
Accounts Receivable of Impaired Asset Group	700			700			700
Other Current Assets of Impaired Asset Group	200			200			200
Current Liabilities of Impaired Asset Group	$ 2,200			$ 2,200			$ 2,200
Percentage of Interest in Tangible Assets in Liquidation Process	57.40%			57.40%			57.40%
Eminence Disposition [Member] | Fixed Assets and Related Deposits [Member]
Property, Plant and Equipment of Impaired Asset Group	$ 3,800			$ 3,800			$ 3,800

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Accrued restructuring action balances	$ 52	$ 897	$ 52
Restructuring costs		242
Cash payments	(472)	(612)
Adjustments	(373)	264
Accrued restructuring action balances	897	1,003
Selling, General and Administrative Expenses [Member]
Restructuring costs			1,399
Employee Severance [Member]
Accrued restructuring action balances	25	570	25
Cash payments	(200)	(370)
Adjustments	(345)	301
Accrued restructuring action balances	570	639
Employee Severance [Member] | Selling, General and Administrative Expenses [Member]
Restructuring costs			649
Asset Impairment [Member]
Accrued restructuring action balances	27	327	27
Restructuring costs		242
Cash payments	(272)	(242)
Adjustments	(28)	(37)
Accrued restructuring action balances	$ 327	$ 364
Asset Impairment [Member] | Selling, General and Administrative Expenses [Member]
Restructuring costs			$ 750

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Jun. 30, 2021
Revenue Recognition
Proceeds from Laboratory Services Reimbursed by Medicare			$ 0.5
Contract with Customer, Liability, Total	$ 25.1	$ 25.1	$ 20
Contract with Customer, Liability, Revenue Recognized	$ 1.9	$ 15.2

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Net sales	$ 290,376	$ 243,552	$ 817,371	$ 672,004
UNITED STATES
Net sales	163,976	131,586	447,045	359,586
UNITED KINGDOM
Net sales	12,920	11,213	37,240	29,599
EMEA, excluding U.K. [Member]
Net sales	55,301	54,552	164,003	147,622
APAC, excluding Greater China [Member]
Net sales	21,100	19,002	58,204	52,744
CHINA
Net sales	26,554	20,467	85,997	63,685
Rest of World [Member]
Net sales	10,525	6,732	24,882	18,768
Consumables [Member]
Net sales	239,171	198,818	657,568	542,909
Instruments [Member]
Net sales	28,899	24,748	92,121	70,849
Service [Member]
Net sales	17,815	14,503	51,426	45,142
Product and Services [Member]
Net sales	285,885	238,069	801,115	658,900
Royalty [Member]
Net sales	$ 4,491	$ 5,483	$ 16,256	$ 13,104

Selected Balance Sheet Data - N

Selected Balance Sheet Data - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 8,563	$ 8,600
Goodwill, Impairment Loss		$ 8,300
Other Noncurrent Assets [Member]
Inventory, Finished Goods, Net of Reserves, Non-current	$ 5,722		$ 5,456

Selected Balance Sheet Data - I

Selected Balance Sheet Data - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Selected Balance Sheet Data
Raw materials	$ 69,263	$ 55,096
Finished goods	64,742	67,108
Inventories, net	$ 134,005	$ 122,204

Selected Balance Sheet Data - P

Selected Balance Sheet Data - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Property and equipment, cost	$ 425,154	$ 397,756
Accumulated depreciation and amortization	(206,756)	(189,849)
Property and equipment, net	218,398	207,907
Land [Member]
Property and equipment, cost	8,603	8,612
Building and Building Improvements [Member]
Property and equipment, cost	225,378	190,661
Machinery and Equipment [Member]
Property and equipment, cost	164,665	149,410
Construction in Progress [Member]
Property and equipment, cost	$ 26,508	$ 49,073

Selected Balance Sheet Data -_2

Selected Balance Sheet Data - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Definite-lived intangibles assets, gross	$ 929,793	$ 941,535
Accumulated amortization	(401,151)	(348,267)
Total	528,642	593,268
In process research and development	22,700	22,700
Total intangible assets, net	551,342	615,968
Developed Technology Rights [Member]
Definite-lived intangibles assets, gross	543,977	552,160
Trade Names [Member]
Definite-lived intangibles assets, gross	147,311	147,640
Customer Relationships [Member]
Definite-lived intangibles assets, gross	228,943	232,493
Patents [Member]
Definite-lived intangibles assets, gross	3,249	2,926
Other Intangible Assets [Member]
Definite-lived intangibles assets, gross	$ 6,313	$ 6,316

Selected Balance Sheet Data - C

Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Selected Balance Sheet Data
Beginning balance			$ 615,968
Other additions	$ 283
Amortization expense	(55,731)
Currency translation	(615)
Eminence impairment (1)	(8,563)	$ (8,600)
Ending balance	$ 551,342		$ 551,342

Selected Balance Sheet Data - E

Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Selected Balance Sheet Data
2022 remainder	$ 18,478
2023	71,725
2024	68,857
2025	65,621
2026	61,876
Thereafter	242,085
Total	$ 528,642	$ 593,268

Selected Balance Sheet Data -_3

Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)
Beginning balance	$ 843,067
Acquisitions	4,407
Eminence impairment	(8,275)
Currency translation	(2,767)
Ending balance	827,618
Protein Sciences [Member]
Beginning balance	392,717
Eminence impairment	(8,275)
Currency translation	(2,588)
Ending balance	381,854
Diagnostics and Genomics [Member]
Beginning balance	450,350
Acquisitions	4,407
Currency translation	(179)
Ending balance	$ 445,764

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands	Apr. 06, 2021	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 9,765
Acquisition of Asuragen, Inc. [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 215,587
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 105,000	$ 105,000	$ 105,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		8,600	25,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ 100	3,700
Goodwill, Purchase Accounting Adjustments			$ (4,407)
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	14 years
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	16 years
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years

Acquisitions - Preliminary and

Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Apr. 06, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Goodwill		$ 827,618		$ 843,067
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 9,765
Acquisition of Asuragen, Inc. [Member]
Current assets, net of cash	$ 10,422	10,422
Equipment and other long-term assets	3,762	3,762
Goodwill	94,970	90,563
Total assets acquired	253,554	249,147
Liabilities	4,003	4,963
Deferred income taxes, net	15,664	10,297
Net assets acquired	233,887	233,887
Payments to Acquire Businesses, Net of Cash Acquired, Total	215,587
Contingent consideration payable	18,300
Net assets acquired	233,887
Goodwill, Purchase Accounting Adjustments		(4,407)
Total assets acquired, adjustments		(4,407)
Liabilities net, adjustments		960
Deferred income taxes, net, adjustments		(5,367)
Acquisition of Asuragen, Inc. [Member] | In Process Research and Development [Member]
Intangible assets	22,700	22,700
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]
Intangible assets	107,000	107,000
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]
Intangible assets	11,700	11,700
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]
Intangible assets	2,000	2,000
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]
Intangible assets	$ 1,000	$ 1,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended			9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	May 31, 2021	Apr. 06, 2021	Dec. 31, 2020	Jun. 30, 2020	Oct. 31, 2018
Interest Expense, Total				$ 2,493		$ 2,660	$ 8,804	$ 10,661
Income Tax Expense (Benefit), Total				8,628		(48)	21,150	16,121
Nonoperating Income (Expense), Total				(21,675)		$ (23,272)	6,317	(27,652)
Payment for Contingent Consideration Liability, Financing Activities							700	0
Exchange Traded Investment Grade Bond Funds [Member]
Investments, Fair Value Disclosure, Total				19,400			19,400
Acquisition of Asuragen, Inc. [Member]
Business Combination, Contingent Consideration, Liability, Total				4,800			4,800				$ 18,300
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				105,000			105,000				$ 105,000
QT Holdings Corporation [Member]
Payment for Contingent Consideration Liability, Financing Activities					$ 4,000
AOCI Attributable to Parent [Member]
Interest Expense, Total							5,214
Income Tax Expense (Benefit), Total							(1,226)
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]
Interest Expense, Total								6,662
Nonoperating Income (Expense), Total								512
Reclassification out of Accumulated Other Comprehensive Income [Member] | Designated as Hedging Instrument [Member] | AOCI Attributable to Parent [Member]
Interest Expense, Total							5,200	6,700
Income Tax Expense (Benefit), Total							1,200	1,700
Nonoperating Income (Expense), Total								$ 500
Forward Starting Swap [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount														$ 380,000
Derivative Notional Amount, Decrease in Period		$ 80,000	$ 100,000
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Current Liabilities [Member]
Derivative Liability, Current				2,000			2,000
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Noncurrent Liabilities [Member]
Derivative Notional Amount, Dedesignated												$ 80,000	$ 80,000
Hedging Liabilities, Noncurrent									$ 7,600
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Forecast [Member]
Derivative Notional Amount, Decrease in Period	$ 200,000
New Forward Starting Swap [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount										$ 200,000
New Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Noncurrent Assets [Member]
Hedging Assets, Noncurrent, Total				9,300			9,300		300
CCXI [Member]
Investments, Total				6,600			6,600		6,600
Investments, Fair Value Disclosure, Total				$ 36,500			36,500		20,000
Warrant Via Net Share Settlement				66,833
Value of warrants									$ 1,400
CCXI [Member] | Exchange Traded Investment Grade Bond Funds [Member]
Investments, Total				$ 20,000			$ 20,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Derivative instruments - cash flow hedges	$ 9,305	$ 275
Total assets	79,656	32,738
Business Combination, Contingent Consideration, Liability, Total	4,800	29,400
Derivative instruments - cash flow hedges	2,046	8,376
Total liabilities	6,846	37,776
Fair Value, Inputs, Level 1 [Member]
Total assets	70,351	31,081
Fair Value, Inputs, Level 2 [Member]
Derivative instruments - cash flow hedges	9,305	275
Total assets	9,305	1,657
Derivative instruments - cash flow hedges	2,046	8,376
Total liabilities	2,046	8,376
Fair Value, Inputs, Level 3 [Member]
Business Combination, Contingent Consideration, Liability, Total	4,800	29,400
Total liabilities	4,800	29,400
Exchanged Traded Securities [Member]
Investments, Fair Value Disclosure	55,851	19,963
Exchanged Traded Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	55,851	18,581
Exchanged Traded Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure		1,382
Certificates of Deposit [Member]
Investments, Fair Value Disclosure	14,500	12,500
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	$ 14,500	$ 12,500

Fair Value Measurements - Liabi

Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2022
Fair value at the beginning of period	$ 9,000	$ 29,400
Change in fair value of contingent consideration	(4,200)	(20,600)
Payments		(4,000)
Fair value at the end of period	$ 4,800	$ 4,800

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements - Narrative (Details) - USD ($) $ in Thousands	Aug. 01, 2018	Mar. 31, 2022	Mar. 31, 2021
Proceeds from Long-term Lines of Credit		$ 90,000	$ 0
Credit Agreement [Member]
Long-term Debt, Total		$ 259,100
Credit Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 250,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.125%
Revolving Credit Facility [Member] | Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 600,000
Line of Credit Facility, Additional Borrowing Capacity	$ 200,000

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	9 Months Ended
	Mar. 31, 2022USD ($)
Variable Lease, Cost	$ 3.4
Fixed Lease, Cost	$ 10.8
Maximum [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years

Leases - Balance Sheet Classifi

Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Leases
Operating lease right of use assets	$ 63,450	$ 73,834
Current operating lease liabilities	11,864	11,602
Noncurrent operating lease liabilities	56,348	$ 67,625
Total operating lease liabilities	$ 68,212
Weighted average remaining lease term (in years): (Year)	6 years 11 months 23 days
Weighted average discount rate:	3.89%

Leases - Cash Paid (Details)

Leases - Cash Paid (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)
Leases
Cash amounts paid on operating lease liabilities	$ 11,221
Right of use assets obtained in exchange for lease liabilities	$ 2,812

Leases - Fair Value of the Leas

Leases - Fair Value of the Lease Liability by Payment Date (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases
Remainder of fiscal 2022	$ 3,686
2023	13,874
2024	12,214
2025	11,057
2026	9,634
Thereafter	27,819
Total	78,284
Less: Amounts representing interest	10,072
Total Lease obligations	$ 68,212

Supplemental Equity and Accum_3

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.32	$ 0.96	$ 0.32	$ 0.96
Interest Expense, Total	$ 2,493	$ 2,660	$ 8,804	$ 10,661
Income Tax Expense (Benefit), Total	8,628	(48)	21,150	16,121
Nonoperating Income (Expense), Total	$ (21,675)	$ (23,272)	6,317	(27,652)
AOCI Attributable to Parent [Member]
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent			(3,988)	(5,503)
Interest Expense, Total			5,214
Income Tax Expense (Benefit), Total			(1,226)
Deferred Income Tax Expense (Benefit), Total			1,706	(2,394)
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent			$ 4,000	5,500
Interest Expense, Total				6,662
Deferred Income Tax Expense (Benefit), Total				1,670
Nonoperating Income (Expense), Total				$ 512

Supplemental Equity and Accum_4

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2022	Mar. 31, 2021
Balances	$ 1,702,531	$ 1,646,955	$ 1,571,234	$ 1,530,854	$ 1,439,285	$ 1,381,192	$ 1,571,234	$ 1,381,192
Balances (in shares)			38,955,484				38,955,484
Net earnings, including noncontrolling interest	60,144	72,059	$ 68,981	45,402	46,144	33,395	$ 201,184	124,941
Other comprehensive income (loss)	4,328	4,808	(6,964)	146	18,987	14,057	$ 2,172	$ 33,190
Common stock issued for exercise of options	10,495	18,605	22,867	16,994	14,268	13,728
Common stock issued for exercise of options (in shares)							555,103	505,137
Common stock issued for restricted stock awards	(159)		(9,765)	(1,801)		(4,890)
Cash dividends	(12,577)	(12,576)	(12,493)	(12,446)	(12,392)	(12,336)
Stock-based compensation expense	8,043	13,701	11,396	10,232	15,471	12,667
Common stock issued to employee stock purchase plan	1,330	6	1,358	1,328		1,463
Employee stock purchase plan expense	25	267	341	411	106	286
Share repurchases	(60,838)	(41,294)		(43,178)
Non-controlling interest in Eminence					8,985
Balances	$ 1,713,322	1,702,531	1,646,955	1,547,942	1,530,854	1,439,285	$ 1,713,322	$ 1,547,942
Balances (in shares)	39,263,444						39,263,444
Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances					(276)
Balances						(276)
Common Stock [Member]
Balances	$ 393	$ 393	$ 390	$ 388	$ 386	$ 385	$ 390	$ 385
Balances (in shares)	39,319,000	39,273,000	38,955,000	38,765,000	38,601,000	38,453,000	38,955,000	38,453,000
Common stock issued for exercise of options	$ 1	$ 1	$ 3	$ 2	$ 2	$ 1
Common stock issued for exercise of options (in shares)	84,000	134,000	295,000	195,000	161,000	117,000
Common stock issued for restricted stock awards			$ 0	$ 0	$ 0	$ 0
Common stock issued for restricted stock awards (in shares)	1,000	1,000	20,000	10,000	3,000	25,000
Common stock issued to employee stock purchase plan			$ 0	$ 0		$ 0
Common stock issued to employee stock purchase plan (in shares)	4,000		3,000	4,000		6,000
Share repurchases	$ (1)	$ (1)		$ (1)
Share repurchases (in shares)	(145,000)	(89,000)		(120,000)
Balances	$ 393	$ 393	$ 393	$ 389	$ 388	$ 386	$ 393	$ 389
Balances (in shares)	39,263,000	39,319,000	39,273,000	38,854,000	38,765,000	38,601,000	39,263,000	38,854,000
Additional Paid-in Capital [Member]
Balances	$ 616,429	$ 583,851	$ 534,411	$ 481,004	$ 448,679	$ 420,536	$ 534,411	$ 420,536
Common stock issued for exercise of options	10,494	18,604	36,345	21,324	16,748	13,727
Common stock issued for restricted stock awards			0	0	0	0
Stock-based compensation expense	8,043	13,701	11,396	10,232	15,471	12,667
Common stock issued to employee stock purchase plan	1,330	6	1,358	1,328		1,463
Employee stock purchase plan expense	25	267	341	411	106	286
Balances	636,321	616,429	583,851	514,299	481,004	448,679	636,321	514,299
Retained Earnings [Member]
Balances	1,145,641	1,119,337	1,085,461	1,104,762	1,073,362	1,057,470	1,085,461	1,057,470
Net earnings, including noncontrolling interest	60,739	80,173	69,615	45,782	46,274	33,395
Common stock issued for exercise of options			(13,481)	(4,332)	(2,482)
Common stock issued for restricted stock awards	(159)		(9,765)	(1,801)	0	(4,890)
Cash dividends	(12,577)	(12,576)	(12,493)	(12,446)	(12,392)	(12,336)
Share repurchases	(60,837)	(41,293)		(43,177)
Balances	1,132,807	1,145,641	1,119,337	1,088,788	1,104,762	1,073,362	1,132,807	1,088,788
Retained Earnings [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances					(276)
Balances						(276)
AOCI Attributable to Parent [Member]
Balances	(59,474)	(64,216)	(57,291)	(64,238)	(83,142)	(97,199)	(57,291)	(97,199)
Other comprehensive income (loss)	4,329	4,742	(6,925)	215	18,904	14,057
Balances	(55,145)	(59,474)	(64,216)	(64,023)	(64,238)	$ (83,142)	(55,145)	(64,023)
Noncontrolling Interest [Member]
Balances	(458)	7,590	8,263	8,938			8,263
Net earnings, including noncontrolling interest	(595)	(8,114)	(634)	(380)	(130)
Other comprehensive income (loss)	(1)	66	(39)	(69)	83
Non-controlling interest in Eminence					8,985
Balances	$ (1,054)	$ (458)	$ 7,590	$ 8,489	$ 8,938		$ (1,054)	$ 8,489

Supplemental Equity and Accum_5

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Balance	$ 1,562,971
Balance	1,714,376
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Balance	(6,193)	$ (13,253)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne	7,757	(13)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)	3,988	5,503
Balance	5,552	(7,763)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(51,098)	(83,946)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne	(9,599)	27,686
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)		0
Balance	(60,697)	(56,260)
AOCI Attributable to Parent [Member]
Balance	(57,291)	(97,199)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne	(1,842)	27,673
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)	3,988	5,503
Balance	$ (55,145)	$ (64,023)

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.8	1.8	0.7	1.6

Earnings Per Share - Shares Use

Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share
Net earnings, including noncontrolling interest	$ 60,144	$ 72,059	$ 68,981	$ 45,402	$ 46,144	$ 33,395	$ 201,184	$ 124,941
Net earnings (loss) attributable to noncontrolling interest	(595)			(380)			(9,343)	(509)
Net earnings attributable to Bio-Techne	60,739			45,782			210,527	125,450
Income allocated to participating securities	(25)			(27)			(95)	(77)
Income available to common shareholders	$ 60,714			$ 45,755			$ 210,432	$ 125,373
Basic (in shares)	39,272			38,856			39,225	38,693
Basic (in dollars per share)	$ 1.55			$ 1.18			$ 5.36	$ 3.24
Income allocated to participating securities	$ (25)			$ (27)			$ (95)	$ (77)
Income available to common shareholders	$ 60,714			$ 45,755			$ 210,432	$ 125,373
Dilutive effect of stock options and restricted stock units (in shares)	1,697			1,820			1,848	1,612
Weighted-average common shares outstanding - diluted	40,969			40,676			41,073	40,305
Diluted (in dollars per share)	$ 1.48			$ 1.12			$ 5.12	$ 3.11

Share-based Compensation (Detai

Share-based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Oct. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			300,000	700,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 480.67	$ 269.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 119.10	$ 57.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			555,103	505,137
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 196.3	$ 108
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 41.7		$ 41.7
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 1 month 6 days
Employee Stock Purchase Plan 2014 [Member]
Share-based Payment Arrangement, Expense		$ 0.4	$ 0.6	0.8
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					200,000
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense	8.7	11.1	35.9	36
Cost of Sales [Member]
Share-based Payment Arrangement, Expense	$ 0.4	$ 0.4	$ 1.1	$ 1.5
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			27,573	23,367
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 470.38	$ 269.87
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			6,896	11,803
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 489.34	$ 264.73

Other Income (Expense) - Narrat

Other Income (Expense) - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
CCXI [Member]
Unrealized Gain (Loss) on Investments, Total	$ 17.2	$ 16.6	$ 16.5	$ 10.2

Other Income (Expense) - Schedu

Other Income (Expense) - Schedule of Components of Other Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Other Income (Expense)
Interest expense	$ (2,493)	$ (2,660)	$ (8,804)	$ (10,661)
Interest income	168	114	606	306
Other non-operating income (expense), net(1)	(19,350)	(20,726)	14,515	(17,297)
Total other income (expense)	$ (21,675)	$ (23,272)	$ 6,317	$ (27,652)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Taxes
Effective Income Tax Rate Reconciliation, Percent, Total	12.50%	(0.10%)	9.50%	11.40%
Income Tax Expense (Benefit), Discrete Tax Items	$ 6.3	$ 11.6	$ 31.6	$ 19.5
Excess Tax Benefit from Share-based Compensation, Operating Activities	3.4	11.7	27.8	19.7
Income Tax Expense (Benefit), Other Immaterial Discrete Tax Items, Net	$ 2.9	$ 0.1	$ 3.8	$ 0.2

Segment Information - Financial

Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Net sales		$ 290,376		$ 243,552	$ 817,371	$ 672,004
Operating income		90,447		68,626	216,017	168,714
Costs recognized on sale of acquired inventory					(1,596)	(91)
Impact of partially owned consolidated subsidiaries(1)		595		380	9,343	509
Eminence impairment					(18,715)	0
Restructuring costs			$ (242)
Corporate general, selling, and administrative expenses		(89,269)		(82,596)	(276,137)	(238,310)
Diagnostics and Genomics [Member]
Restructuring costs	$ (1,200)	300	$ (500)
Operating Segments [Member]
Operating income		116,155		99,400	317,879	266,985
Costs recognized on sale of acquired inventory				(68)	(1,596)	(91)
Amortization of acquisition related intangible assets		(18,173)		(15,222)	(54,942)	(45,750)
Impact of partially owned consolidated subsidiaries(1)		(892)		(699)	(3,446)	(906)
Acquisition related expenses		3,710		(1,731)	19,328	(6,289)
Eminence impairment					(18,715)
Stock based compensation, inclusive of employer taxes		(9,056)		(11,968)	(37,731)	(41,525)
Restructuring costs		291			(1,638)	(142)
Operating Segments [Member] | Protein Sciences [Member]
Net sales		213,176		185,623	615,332	512,248
Operating income		96,750		88,983	280,131	239,788
Operating Segments [Member] | Diagnostics and Genomics [Member]
Net sales		77,679		58,093	203,191	160,687
Operating income		19,405		10,417	37,748	27,197
Intersegment Eliminations [Member]
Net sales		(479)		(164)	(1,152)	(931)
Corporate, Non-Segment [Member]
Corporate general, selling, and administrative expenses		$ (1,588)		$ (1,086)	$ (3,122)	$ (3,568)